As a sodium-glucose cotransporter 2 (SGLT2) inhibitor, Empagliflozin holds a crucial position in diabetes management and cardiorenal protection.

Indications for Empagliflozin

Heart Failure Treatment and Risk Prevention

Used to reduce the risk of cardiovascular death and hospitalization due to heart failure in adult patients with heart failure.

Chronic Kidney Disease (CKD) Progression Control

Indicated for adult patients with chronic kidney disease who are at risk of disease progression.

Specific uses include: reducing the risk of persistent estimated glomerular filtration rate (eGFR) decline.

Decreasing the incidence of end-stage renal disease (ESRD).

Lowering the risk of cardiovascular death and hospitalization.

Management of Cardiovascular Complications in Diabetes

Used to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus who have confirmed cardiovascular disease.

Adjunctive Therapy for Blood Glucose Control

As an adjunct to diet and exercise, it improves blood glucose control in adult and pediatric patients aged 10 years and older with type 2 diabetes mellitus.

Populations for Whom Use Is Not Recommended

Blood glucose control in patients with type 1 diabetes mellitus (may increase the risk of ketoacidosis).

Blood glucose control in patients with type 2 diabetes mellitus who have an eGFR below 30 mL/min/1.73 m².

Patients with Polycystic Kidney Disease

Patients who have recently received intravenous immunosuppressive therapy.

Patients receiving more than 45 mg of prednisone or an equivalent medication for kidney disease treatment.

Absolute Contraindications

Contraindicated in patients with a hypersensitivity to empagliflozin or any component of this product, including those who have experienced severe allergic reactions such as angioedema.

Specifications and Properties of Empagliflozin

Specification Classification

1. 10 mg tablets

2. 25 mg tablets

Appearance Description

10 mg tablets: Light yellow, round, biconvex, film-coated tablets with beveled edges. One side is engraved with "S10", and the other side bears the Boehringer Ingelheim logo.

25 mg tablets: Light yellow, oval, biconvex, film-coated tablets. One side is engraved with "S25", and the other side bears the Boehringer Ingelheim logo.

Storage Methods for Empagliflozin

Storage Environment Requirements

Storage temperature range: 20°C - 25°C (68°F - 77°F).

Allowable short-term temperature fluctuation range: 15°C - 30°C (59°F - 86°F).

Packaging Information

Packaged in well-sealed containers. Bottle packaging is available in two specifications: 30 tablets per bottle and 90 tablets per bottle. Blister packaging is also available, with each box containing 3 blister cards and 10 tablets per card.